Why the study?
Hypertrophic cardiomyopathy remains underdiagnosed despite an increasing number of effective treatment interventions that can improve care.
Answers are grounded in this paper and cite their sources.
Multimodality imaging is an integral tool for the comprehensive assessment, risk stratification, and targeted management of hypertrophic cardiomyopathy.
Hypertrophic cardiomyopathy remains underdiagnosed despite a growing number of effective treatment interventions that can improve care. Multimodality imaging has become integral to diagnosing and managing hypertrophic cardiomyopathy, providing a comprehensive assessment of the disease. In particular, it enhances the diagnostic accuracy and deepens the understanding of the mechanisms underlying patient symptoms, enabling targeted therapeutic approaches. Additionally, multimodality imaging allows for better risk stratification, assessment of therapy response, and guidance of interventions to deliver personalized medicine. The practical tools outlined in this review can help providers integrate multimodality imaging strategies to provide better care and improve the patient experience.
No takes yet. Share an insight, caveat, or question.
Dalsania et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: